Overview

A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable Schizophrenia

Status:
Completed

Trial end date:
2019-11-06

Target enrollment:

Participant gender:

Summary

The purpose of the study is to determine whether motivation/reward deficits observed in schizophrenia are attenuated and whether cognitive impairment associated with schizophrenia is improved by add-on TAK-041 administration to antipsychotics in participants with stable schizophrenia.

Phase:

Phase 2

Details

Lead Sponsor:

Neurocrine Biosciences
Takeda

Collaborator:

Takeda

Treatments:

Antipsychotic Agents